Adverse events at 12- and 24-month follow-up in the entire population (Cohort B1 and B2) (intent-to-treat population)
| Cohort B1 and B2 12-Month follow-up | Cohort B1 and B2 24-Month Follow-up | |||||
|---|---|---|---|---|---|---|
| Small vessels (<2.5 mm) (N=41) | Large vessels (≥2.5 mm) (N=60) | p Value | Small vessels (<2.5 mm) (N=41) | Large vessels (≥2.5 mm) (N=60) | p Value | |
| MACE (Cardiac Death, MI, ID-TLR) | 7.3% (3/41) | 6.7% (4/60) | 1.0000 | 7.3% (3/41) | 10.2% (6/59) | 0.7335 |
| Cardiac death | 0.0% (0/41) | 0.0% (0/60) | NA | 0.0% (0/41) | 0.0% (0/59) | NA |
| Myocardial infarction (MI) | 4.9% (2/41) | 1.7% (1/60) | 0.5645 | 4.9% (2/41) | 1.7% (1/59) | 0.5662 |
| QMI | 0.0% (0/41) | 0.0% (0/60) | NA | 0.0% (0/41) | 0.0% (0/59) | NA |
| NQMI | 4.9% (2/41) | 1.7% (1/60) | 0.5645 | 4.9% (2/41) | 1.7% (1/59) | 0.5662 |
| ID-TLR (PCI) | 2.4% (1/41) | 5.0% (3/60) | 0.6445 | 2.4% (1/41) | 8.5% (5/59) | 0.3962 |
| Scaffold thrombosis | 0.0% (0/41) | 0.0% (0/60) | NA | 0.0% (0/41) | 0.0% (0/60) | NA |
ID-TLR, ischaemia driven target lesion revascularization; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; QMI, Q wave myocardial infarction; NQMI, non-Q wave myocardial infarction.